- Atai Life Sciences B.V., backed by billionaire investor Peter Thiel, has announced terms for its initial public offering.
- See the SEC prospectus here.
- The German company said it was looking to raise around $214.3 million through a U.S. IPO, targeting a valuation of about $2.3 billion.
- The biotech startup, which explores the use of psychedelic treatments for mental health disorders, said it planned to sell around 14.29 million shares priced between $13 and $15 per share.
- Launched in 2018, Atai has raised $362.3 million in cash so far.
- Atai will be listed on the NASDAQ and will trade under the ticker symbol “ATAI.”
- The company has built a pipeline of 10 development programs and six enabling technologies, each supported by its internal development and operational infrastructure.
- One of its companies, Recognify Life Sciences, has initiated a Phase 2a trial in the U.S.
- The company expects to initiate a Phase 2 trial for another program in 2021 and an additional three Phase 2 trials for other programs in 2022.
- In April, the company filed to raise $100 million in an IPO.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.